Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Mountain States] => https://www.survivornet.com/glioma-mountain-states/
[Southeast] => https://www.survivornet.com/southeast/
) )
Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma Summary The purpose of this clinical research study is to compare pharmacokinetics of ipilimumab manufactured by two different processes
View Eligibility Criteria Eligibility Criteria Inclusion Criteria: Histologic diagnosis of malignant melanoma Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Measurable/evaluable disease per modified World Health Organization (mWHO) criteria Exclusion Criteria: Active Brain Metastasis Primary ocular or mucosal melanoma Prior Autoimmune disease Inadequate hematologic, hepatic or renal function Use of immunosuppressants Prior treatment with a CD137 agonist or cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
The Angeles Clinic & Research Inst. Los Angeles California, 90025, United States
California Pacific Medical Center San Francisco California, 94115, United States
H Lee Moffitt Cancer Center Tampa Florida, 33612, United States
Memorial Sloan Kettering Cancer Center New York New York, 11065, United States
Carolinas Medical Center Charlotte North Carolina, 28204, United States
St Luke'S Hospital And Health Network Bethlehem Pennsylvania, 18015, United States
Seattle Cancer Care Alliance Seattle Washington, 98109, United States
How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up